Gene Therapy Company Immusoft Raises $2.74M in Funding

immusoftImmusoft, a Seattle, Wash.-based gene therapy company, closed on $2.74m of a $3m funding round.

The round, which was oversubscribed and expected to be closed soon, was led by Founders Fund’s FF Science and Technium Partners.

The company intends to use the funds to submit its Investigational New Drug application and expand business operations.

Founded in 2009 by Matthew Scholz, CEO, Immusoft has developed the Immune System Programming (ISP™) technology, which reprograms patient B cells to treat diseases to produce gene-encoded medicines (biologics).



Join the discussion